Key Highlights

  • 11.72% is the indicated pre-market gain for Neuronetics, Inc. (NASDAQ:STIM) on November 18, 2026, lifting the price to USD 1.43 from a calculated prior close of USD 1.28, a calculated USD 0.15 move.
  • 1.60 USD was the per-share price of the underwritten offering of 18,750,000 shares priced on November 10, 2026, for gross proceeds of about USD 30 million, with a 30-day option on 2,812,500 more shares.
  • 12.5% is the third-quarter 2026 Revenue growth to USD 42.0 million, led by Greenbrook clinic revenue of USD 26.2 million and NeuroStar revenue of USD 15.8 million, with gross Margin of 52.2% versus 45.9%.
  • 27.9 million USD is total cash at the end of the third quarter, including USD 22.1 million of cash equivalents and USD 5.8 million restricted, against a net loss of USD 1.6 million for the quarter.

What Moved Neuronetics, Inc. (NASDAQ:STIM) in Pre-Market Trading on November 18, 2026 (+USD 0.15, +11.72%)

The indicated pre-market price for Neuronetics, Inc. (NASDAQ:STIM) is USD 1.43 on November 18, 2026, a pre-market move of +11.72%. The calculated prior close is USD 1.28 (USD 1.43 divided by 1.1172), and the calculated USD move is +USD 0.15. The indicated price is about 10.6% below the USD 1.60 offering price (calculated). A corroborated market Capitalization and pre-market Volume were not found.

The Rationale: Rebound After the USD 30 Million Offering for Neuronetics, Inc. (NASDAQ:STIM)

No new company announcement dated November 18, 2026 was identified in published coverage. The move follows the offering launched on November 10, 2026, with William Blair as lead bookrunner alongside BTIG and Canaccord Genuity, after which published coverage reported a decline in the shares. Closing was expected on or about November 12, 2026. Proceeds repay part of the term Loan under the Perceptive facility, and Amendment No. 6 dated November 5, 2026 requires a prepayment of no less than USD 15 million, ending automatically if conditions are unmet by November 30, 2026. As general context, shares often rebound after offering-related selling.

Valuation, Liquidity and Risks for Neuronetics, Inc. (NASDAQ:STIM)

Third-quarter Operating Income was USD 0.5 million against a USD 7.3 million loss a year earlier, operating expenses fell 13% to USD 21.3 million, and adjusted EBITDA was USD 1.9 million. The net loss attributable to shareholders was USD 1.7 million, or USD 0.02 per share, versus USD 9.0 million. Full-year revenue guidance of USD 160 million to USD 164 million was reaffirmed. Risks include dilution from 18,750,000 new shares, a low share price, the going-concern language noted in recent filings, Debt covenants and execution at the Greenbrook clinics.

Where Things Stand

Neuronetics, Inc. (NASDAQ:STIM) is indicated up 11.72% in pre-market trading on November 18, 2026, at USD 1.43, a calculated USD 0.15 above a prior close of USD 1.28. No same-day catalyst was identified in published coverage, and the shares follow the USD 1.60 offering priced on November 10, 2026. Third-quarter revenue grew 12.5% to USD 42.0 million, the net loss narrowed to USD 1.6 million and cash was USD 27.9 million. Dilution, debt covenants and a thin pre-market book are key risks, pre-market moves can reverse at the 9:30 a.m. ET open, and this is not Investment advice.